Back to today’s briefing

Story perspectives

Revolutionary Gene Therapy Cuts Cholesterol by 53%!

7/13/2025

50 5

Summary

Story summary

VERVE-102, a groundbreaking gene therapy, is making waves in the fight against high cholesterol. In clinical trials, a single dose slashed LDL cholesterol levels by an impressive 53%, targeting the PCSK9 gene through innovative base editing. With Verve Therapeutics now under Lilly's wing, hopes are high for swift FDA approval.

1 of 1

Story summary

VERVE-102, a groundbreaking gene therapy, is making waves in the fight against high cholesterol. In clinical trials, a single dose slashed LDL cholesterol levels by an impressive 53%, targeting the PCSK9 gene through innovative base editing. With Verve Therapeutics now under Lilly's wing, hopes are high for swift FDA approval.